<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00414271</url>
  </required_header>
  <id_info>
    <org_study_id>JS 0420</org_study_id>
    <secondary_id>NA_00044000</secondary_id>
    <nct_id>NCT00414271</nct_id>
  </id_info>
  <brief_title>Neo-adjuvant Chemotherapy in Locally Advanced Gastric Cancer</brief_title>
  <official_title>A Phase II Study of Neo-adjuvant Chemotherapy in Locally Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thymidylate Synthase (TS) is a key enzyme in the synthesis of DNA and the target enzyme
      inhibited by 5-fluorouracil (5-FU). TS level in the tumour cells has been reported as
      predictive to response to 5-FU and a prognostic factor in colorectal and gastric cancer
      patients. We plan to study TS by immunohistochemistry (IHC) in the paraffin blocks of tumour
      tissue.

      A combined comparative genomic hybridization (CGH) and expression microarray analysis of
      gastric cancer specimens before and after neoadjuvant chemotherapy. CGH will be performed
      using standard technique routinely done in Dr Patrick Tan's laboratory at the National Cancer
      Centre, which determines the gain or loss of DNA copies of each chromosome. Total RNA will be
      extracted from at least one biopsy sample which contains at least 50% cancer cells by
      homogenization of the tumour tissue and tri-sol method. 5 ug of RNA were amplified and
      hybridized with the C-DNA microarrays of 18K targets.

      Primary Objective 1. Feasibility and safety of pre-operative chemotherapy in locally advanced
      gastric cancer.

      Secondary Objective

        1. Complete clinical and pathological response rates to pre-operative chemotherapy in
           locally advanced gastric cancer

        2. Complete resection rate.

        3. Time to recurrence, disease free and overall survival

        4. Correlation of clinical outcome with (Runt-related transcription factor) RUNX-3
           methylation status and Thymidylate synthetase in the tumor tissue.

        5. Correlation of CGH and gene expression profile and their changes after chemotherapy with
           clinical outcome.

           Patients may be included in the study only if they meet all of the following criteria:

           Age at least 18 years. Histologic or cytologic diagnosis of adenocarcinoma of stomach or
           gastric cardia (Siewert Classification Type III) Preoperative Stage T3-4NxM0 by
           endoscopic ultrasound, CT of the abdomen/pelvis and laparoscopy. (CT of the chest if it
           is a cardia lesion).

           Absence of malignant cells in peritoneal lavage fluid during laparoscopic examination.

           Patients must not have received any prior chemotherapy or hormonal therapy for the
           treatment of gastric cancer.

           Karnofsky performance status of 70 or higher. Estimated life expectancy of at least 12
           weeks.

           Adequate organ function including the following:

           - Bone marrow: White blood cells (WBC) at least 3.5 x 109/L Absolute neutrophil
           (segmented and bands) count (ANC) at least 1.5 x 109/L Platelets at least 100 x 109/L
           Haemoglobin at least 9g/dL

           - Hepatic: Bilirubin within upper limit of normal (ULN), Aspartate transaminase (ALT) or
           Alanine transaminase (AST) not more than 2.5x ULN Alkaline phosphatase not more than
           2.5x ULN.

           - Renal: creatinine not more than 1.5x ULN Signed informed consent by patient or legal
           representative. Patients with reproductive potential must use an approved contraceptive
           method if appropriate (eg, intrauterine device, birth control pills, or barrier device)
           during and for three months after the study. Females with childbearing potential must
           have a negative serum pregnancy test within 7 days prior to study enrollment.

           The study plans to recruit 30 patients in 12-18 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Pathological Response</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Number of participants who completed neoadjuvant chemotherapy and underwent repeat CT and endoscopic ultrasound (EUS) with pathological complete response (pCR), partial response in the primary tumor, stable disease or progressive disease as defined by EUS criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 8 years</time_frame>
    <description>Median number of months participants alive at the time of observation. Calculated using Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival as Measured by Number of Participants Without Disease Progression.</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility and Safety of Pre-operative Chemotherapy in Locally Advanced Gastric Cancer as Assessed by Number of Participants Who Experienced Adverse Events Grade 3 or Higher as Defined by CTCAE.</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Number of participants who experience Grade 3/4 neutropenia, Grade 3 nausea or Grade 3 diarrhea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of CGH and Gene Expression Profile and Their Changes After Chemotherapy With the Same Clinical Outcomes</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Initially, we also planned to study the thymidylate synthetase expression, methylation of RUNX-3 gene[24] and comprehensive genomic hybridization[25] before and after chemotherapy to look for biomarkers of response and prognostic indication. But due to the lack of pCR and the small number of patients enrolled, we stopped the correlative studies.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Stage T3-4NxM0 Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel and Capecitabine in gastric cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous docetaxel 60 mg/m2 on day 1 and oral capecitabine 900 mg/m2 two times per day from day 1 to day 14 every 3 weeks for 2 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 60 mg/m2 IV on day 1</description>
    <arm_group_label>Docetaxel and Capecitabine in gastric cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 900 mg/m2 PO two times per day from day 1 to day 14 every 3 weeks for 2 cycles.</description>
    <arm_group_label>Docetaxel and Capecitabine in gastric cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal 18 years.

          -  Histologic or cytologic diagnosis of adenocarcinoma of stomach or gastric cardia
             (Siewert Classification Type III)

          -  Preoperative Stage T3-4NxM0 by endoscopic ultrasound, CT of the abdomen/pelvis and
             laparoscopy. (CT of the chest if it is a cardia lesion).

          -  Absence of malignant cells in peritoneal lavage fluid during laparoscopic examination.

          -  Patients must not have received any prior chemotherapy or hormonal therapy for the
             treatment of gastric cancer.

          -  Karnofsky performance status of 70 or higher.

          -  Estimated life expectancy of at least 12 weeks.

          -  Adequate organ function including the following:

          -  Bone marrow:

               -  White blood cells (WBC) greater than or equal 3.5 x 109/L

               -  Absolute neutrophil (segmented and bands) count (ANC) greater than or equal 1.5 x
                  109/L

               -  Platelets greater than or equal 100 x 109/L

               -  Haemoglobin greater than or equal 9g/dL

          -  Hepatic:

               -  Bilirubin within upper limit of normal (ULN),

               -  ALT or AST less than or equal 2.5x ULN

               -  Alkaline phosphatase less than or equal 2.5x ULN.

          -  Renal:

               -  creatinine less than or equal 1.5x ULN

          -  Signed informed consent by patient or legal representative.

          -  Patients with reproductive potential must use an approved contraceptive method if
             appropriate (eg, intrauterine device, birth control pills, or barrier device) during
             and for three months after the study. Females with childbearing potential must have a
             negative serum pregnancy test within 7 days prior to study enrollment.

        Exclusion Criteria:

          -  Prior treatment for locally advanced or metastatic gastric cancer. Any metastatic
             disease will render patient ineligible according to American Joint Committee on Cancer
             (AJCC) staging manual. (See appendix 11.4).

          -  Treatment within the last 30 days with any investigational drug.

          -  Concurrent administration of any other cancer therapy, including cytotoxic
             chemotherapy, hormonal therapy, and immunotherapy.

          -  Active infection that in the opinion of the investigator would compromise the
             patient's ability to tolerate therapy.

          -  Pregnancy.

          -  Breast-feeding.

          -  Serious concomitant disorders that would compromise the safety of the patient or
             compromise the patient's ability to complete the study, at the discretion of the
             investigator.

          -  Poorly controlled diabetes mellitus with fasting blood sugar &gt; 18 mmol/L(mM).

          -  Second primary malignancy that is clinically detectable at the time of consideration
             for study enrollment.

          -  History of significant neurological or mental disorder, including seizures or
             dementia.

          -  History of hypersensitivity to drugs formulated in Tween 80, the vehicle used for
             commercial docetaxel formulations.

          -  History of hypersensitivity to 5-fluorouracil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Chang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Singapore International Medical Center</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>https://bmjopengastro.bmj.com/content/3/1/e000095</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>December 20, 2006</study_first_submitted>
  <study_first_submitted_qc>December 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2006</study_first_posted>
  <results_first_submitted>May 27, 2016</results_first_submitted>
  <results_first_submitted_qc>May 31, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 25, 2019</results_first_posted>
  <last_update_submitted>May 31, 2019</last_update_submitted>
  <last_update_submitted_qc>May 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastric cancer, neo-adjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Docetaxel and Capecitabine in Gastric Cancer</title>
          <description>Intravenous docetaxel 60 mg/m2 on day 1 and oral capecitabine 900 mg/m2 two times per day from day 1 to day 14 every 3 weeks for 2 cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>&gt;= 18 years old</population>
      <group_list>
        <group group_id="B1">
          <title>Docetaxel and Capecitabine in Gastric Cancer</title>
          <description>Intravenous docetaxel 60 mg/m2 on day 1 and oral capecitabine 900 mg/m2 two times per day from day 1 to day 14 every 3 weeks for 2 cycles.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>locally advanced gastric cancer</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Pathological Response</title>
        <description>Number of participants who completed neoadjuvant chemotherapy and underwent repeat CT and endoscopic ultrasound (EUS) with pathological complete response (pCR), partial response in the primary tumor, stable disease or progressive disease as defined by EUS criteria.</description>
        <time_frame>up to 5 years</time_frame>
        <population>Only 15 of the participants who completed neoadjuvant chemotherapy and underwent repeat CT and EUS had measurable tumors by both imaging methods.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label, Single Arm</title>
            <description>Capecitabine, docetaxol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pathological Response</title>
          <description>Number of participants who completed neoadjuvant chemotherapy and underwent repeat CT and endoscopic ultrasound (EUS) with pathological complete response (pCR), partial response in the primary tumor, stable disease or progressive disease as defined by EUS criteria.</description>
          <population>Only 15 of the participants who completed neoadjuvant chemotherapy and underwent repeat CT and EUS had measurable tumors by both imaging methods.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pathological complete response (pCR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Median number of months participants alive at the time of observation. Calculated using Kaplan-Meier method.</description>
        <time_frame>up to 8 years</time_frame>
        <population>1 participant was lost to follow-up after progression from neoadjuvant chemotherapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label, Single Arm</title>
            <description>Capecitabine, docetaxol</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Median number of months participants alive at the time of observation. Calculated using Kaplan-Meier method.</description>
          <population>1 participant was lost to follow-up after progression from neoadjuvant chemotherapy.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" lower_limit="7.4" upper_limit="84.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival as Measured by Number of Participants Without Disease Progression.</title>
        <time_frame>up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label, Single Arm</title>
            <description>Capecitabine, docetaxol</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival as Measured by Number of Participants Without Disease Progression.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Feasibility and Safety of Pre-operative Chemotherapy in Locally Advanced Gastric Cancer as Assessed by Number of Participants Who Experienced Adverse Events Grade 3 or Higher as Defined by CTCAE.</title>
        <description>Number of participants who experience Grade 3/4 neutropenia, Grade 3 nausea or Grade 3 diarrhea.</description>
        <time_frame>up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label, Single Arm</title>
            <description>Capecitabine, docetaxol</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility and Safety of Pre-operative Chemotherapy in Locally Advanced Gastric Cancer as Assessed by Number of Participants Who Experienced Adverse Events Grade 3 or Higher as Defined by CTCAE.</title>
          <description>Number of participants who experience Grade 3/4 neutropenia, Grade 3 nausea or Grade 3 diarrhea.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3/4 neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of CGH and Gene Expression Profile and Their Changes After Chemotherapy With the Same Clinical Outcomes</title>
        <description>Initially, we also planned to study the thymidylate synthetase expression, methylation of RUNX-3 gene[24] and comprehensive genomic hybridization[25] before and after chemotherapy to look for biomarkers of response and prognostic indication. But due to the lack of pCR and the small number of patients enrolled, we stopped the correlative studies.</description>
        <time_frame>up to 5 years</time_frame>
        <population>Data was not collected to assess this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label, Single Arm</title>
            <description>Capecitabine, docetaxol</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of CGH and Gene Expression Profile and Their Changes After Chemotherapy With the Same Clinical Outcomes</title>
          <description>Initially, we also planned to study the thymidylate synthetase expression, methylation of RUNX-3 gene[24] and comprehensive genomic hybridization[25] before and after chemotherapy to look for biomarkers of response and prognostic indication. But due to the lack of pCR and the small number of patients enrolled, we stopped the correlative studies.</description>
          <population>Data was not collected to assess this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Open Label, Single Arm</title>
          <description>Capecitabine, docetaxol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>One patient developed a myocardial infarction after the first cycle of chemotherapy and was taken off protocol.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade1</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof Alex Chang</name_or_title>
      <organization>Johns Hopkins Singapore</organization>
      <phone>+65 68802220</phone>
      <email>alexchang@imc.jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

